Torquay

Researchers are evaluating Ratutrelvir 83-0060, a drug that inhibits the main protease of SARS-CoV-2, along with Paxlovid Nirmatrelvir plus Ritonavir, to understand their safety and effectiveness in adults with mild to moderate COVID-19 who are not hospitalized. This open-label, randomized Phase 2a study aims to determine a safe and effective dose of Ratutrelvir and compare it with standard care, providing important information on how these treatments may help manage COVID-19 symptoms and recovery. Participants will be assigned to receive either Ratutrelvir or Paxlovid alongside standard care. The study is multicenter and open-label, meaning both researchers and participants know which treatment is given. The trial includes an experimental group receiving Ratutrelvir, a comparator group receiving Paxlovid, and a non-randomized group receiving Ratutrelvir. Treatment is given during the study period, and the research team monitors the drugs concentration in the blood to understand how it behaves in the body. During the 28-day study period, participants will be closely monitored for safety based on the occurrence and severity of any adverse events. The team will assess how long it takes for COVID-19 symptoms to improve and recover fully. Blood samples will be collected up to day 11 to analyze drug levels. Participants will undergo symptom evaluations regularly, and their health will be tracked throughout the study to ensure safety and gather data on treatment effects.

Researchers are studying the safety of BHV-1300 as a treatment for adults with Graves Disease. This Phase 1 trial aims to explore how BHV-1300 affects biomarkers related to this condition to better understand its impact. The study is led by Biohaven Therapeutics Ltd. and focuses on monitoring the treatments safety profile over time. Participants will receive BHV-1300, which is given as a subcutaneous injection. This open-label study does not include placebo control or blinding, and all participants receive the same treatment. The treatment period and follow-up extend up to 52 weeks to observe effects and any adverse events. During the study, participants will be closely monitored for serious adverse events, side effects that may lead to stopping treatment, and laboratory abnormalities. Researchers will regularly assess health status and collect data on disease-specific biomarkers. The total duration of participation is approximately one year, ensuring comprehensive safety and effect evaluations.